Advertisement
CGRP Phase IIb is a multi-centered, double-blind, placebo controlled,randomized cross-over study to evaluate the effects of inhaled CGRP onclinical and inflammatory parameters in adult patients with mild asthmafollowing allergen challenge test. A total of 16 patients will be enrolled intwo randomized one week treatment periods (either 5mg CGRP b.i.d. or placebo).
Advertisement
"Having already successfully demonstrated the CGRP bronchoprotectiveefficacy for the first time in human asthmatics in the previous Phase IIastudy and based on the compelling results previously obtained in pre-clinicalstudies, we are now looking forward to demonstrating its anti-inflammatoryproperties. Positive results from this study would confirm CGRP's potential asa strong alternative to the usual combination asthma therapies." said Dr.Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc.
About Akela CGRP
Akela CGRP is a 37 amino acid natural neuropeptide produced in the lung inresponse to allergic stimuli. As a potential drug, it has demonstrated inpreclinical studies a profile that could make it an ideal anti-asthmatic drugcandidate with bronchodilatory, bronchoprotecting and anti-inflammatoryproperties.
About Akela Pharma Inc.
Akela Pharma is an integrated drug development company focused ondeveloping therapies for the growing multi-billion dollar inhalation, pain andCNS markets. Its lead product, for the treatment of breakthrough cancer pain,is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R)dry powder inhaler platform. Its pipeline also includes therapeutics forasthma, COPD, growth hormone deficiencies and abuse deterrent formulations forcontrolled substances.
Akela's common shares trade on The Toronto Stock Exchange ("TSX") underthe symbol "AKL" with 82.3 million shares outstanding.This news release contains certain forward-looking statements that reflect the current views and/or expectations of AKELA Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
SOURCE Akela Pharma Inc.
